Get started
Author

Mikołaj Matłoka

Observed names: M. Matloka, M. Matłoka, Matłoka, Mikołaj, Mikolaj Matloka
ORCID: 0000-0001-9891-1838
Observed ORCID: 0000-0001-9891-1838
OpenAlex ID: A5036599898
Mouse phenotyping
2010 · Helmut Fuchs, Valérie Gailus-Durner, et al. · Methods · 135
Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists
2021 · Piotr Pankiewicz, Marcin Szybiński, et al. · Pharmaceuticals · 41
PDF
Virtual screening-driven discovery of dual 5-HT6/5-HT2A receptor ligands with pro-cognitive properties
2019 · Jakub Staroń, Rafał Kurczab, et al. · European Journal of Medicinal Chemistry · 38
PDF
Synthesis and characterization of novel classes of PDE10A inhibitors - 1H-1,3-benzodiazoles and imidazo[1,2-a]pyrimidines
2018 · Rafał Moszczyński-Pętkowski, Jakub Majer, et al. · European Journal of Medicinal Chemistry · 29
2-Aminoimidazole-based antagonists of the 5-HT6 receptor – A new concept in aminergic GPCR ligand design
2019 · Adam S. Hogendorf, Agata Hogendorf, et al. · European Journal of Medicinal Chemistry · 23
Pyrroloquinoline scaffold-based 5-HT6R ligands: Synthesis, quantum chemical and molecular dynamic studies, and influence of nitrogen atom position in the scaffold on affinity
2018 · Katarzyna Grychowska, Rafał Kurczab, et al. · Bioorganic & Medicinal Chemistry · 16
Discovery and development of CPL207280 as new GPR40/FFA1 agonist
2021 · Mateusz Mach, Katarzyna Bazydło-Guzenda, et al. · European Journal of Medicinal Chemistry · 15
Distinct cognitive and discriminative stimulus effects of ketamine enantiomers in rats
2020 · Piotr Popik, Shaun Yon-Seng Khoo, et al. · Pharmacology Biochemistry and Behavior · 14
PDF
Esketamine inhaled as dry powder: Pharmacokinetic, pharmacodynamic and safety assessment in a preclinical study
2022 · Mikołaj Matłoka, Sylwia Janowska, et al. · Pulmonary Pharmacology & Therapeutics · 13
CPL207280, a Novel G Protein–Coupled Receptor 40/Free Fatty Acid Receptor 1–Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals
2021 · Katarzyna Bazydlo-Guzenda, Pawel Buda, et al. · Molecular Pharmacology · 13
PDF
Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease
2021 · Tomasz Lenda, Krystyna Ossowska, et al. · European Journal of Pharmacology · 11
PDF
A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects
2022 · Mikolaj Matloka, Sylwia Janowska, et al. · Frontiers in Pharmacology · 9
PDF
Simultaneous 5-HT1BR agonist/5-HT6R antagonist action as a potential treatment of Parkinson’s disease and its comorbidities
2024 · Paweł Zajdel, Mikołaj Matłoka, et al. · Journal of Pharmacology and Experimental Therapeutics · 8
Quetiapine and novel PDE10A inhibitors potentiate the anti-BuChE activity of donepezil
2020 · Joanna Sikora, Maria Podsiedlik, et al. · Journal of Enzyme Inhibition and Medicinal Chemistry · 8
Safety and pharmacokinetics study of inhaled esketamine after a single dose in healthy volunteers
2019 · S. Janowska, E. Tratkiewicz, et al. · European Neuropsychopharmacology · 7
Cell-based assay for low- and high-scale screening of the Wnt/β-catenin signaling modulators
2015 · Maria Mazur, Anna Bujak, et al. · Analytical Biochemistry · 7
P.164 Safety and pharmacokinetic study of inhaled Esketamine after a multiple dose in healthy volunteers
2019 · S. Janowska, E. Tratkiewicz, et al. · European Neuropsychopharmacology · 2
CPL500036 – a novel inhibitor of phosphodiesterase 10A – attenuates the development of L-DOPA-induced dyskinesias in 6-OHDA lesioned rats
2022 · M. Matłoka, T. Lenda, et al. · Neuroscience Applied · 1
PDF
P.0078 Inflammatory cytokine plasma levels correlation with MADRS score in patients with treatment-resistant major depression after dry-powder inhaled esketamine administration
2021 · M. Matłoka, A. Gajos-Draus, et al. · European Neuropsychopharmacology · 1
CCDC 2076005: Experimental Crystal Structure Determination
2021 · Mach, Mateusz, Bazydło-Guzenda, Katarzyna, et al. · The Cambridge Structural Database · 1
P.105 The study of molecular changes induced by CPL500-036, a potential novel anti-dyskinetic drug, in 6-OHDA rat model of Parkinson's disease
2020 · A. Gajos-Draus, K. Mulewski, et al. · European Neuropsychopharmacology · 1
PDE10A Inhibition in Schizophrenia: A Randomised, Placebo-Controlled Phase 2 Study of Alofropodect (CPL’36) in Patients Experiencing Acute Schizophrenia
2026 · Maciej Wieczorek, Napoleon Waszkiewicz, et al. · CNS Drugs
PDF
Uncovering mechanistic differences among PDE10A inhibitors: a multilevel molecular, functional and behavioral comparison underlying the clinical efficacy of CPL’36
2026 · J. Krzemień, S. Kokhanovska, et al. · Neuroscience Applied
A novel functional platform for the discovery of trace amine-associated receptor 1 agonists with dual gαs and gαq activity
2024 · S. Kokhanovska, K. Skowrońska, et al. · Neuroscience Applied
Repeated, 4-week dosing of CPL500036, a novel phosphodiesterase 10A inhibitor, does not induce tolerance to its antipsychotic-like action
2023 · J. Krzemień, A. Nikiforuk, et al. · Neuroscience Applied
Works count: 33
Citation count: 393
H-index: 11
I10-index: 11
Year
Topic
Type